Tag: angiotensin receptor blockers arbs market forecast

  • 2024 Angiotensin Receptor Blockers ARBs Market Analysis: Market Size, Key Drivers, and Segment Insights

    2024 Angiotensin Receptor Blockers ARBs Market Analysis: Market Size, Key Drivers, and Segment Insights

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What Will Be the Growth Trajectory of the Angiotensin Receptor Blockers ARBs Market from 2024 to 2033?

    The market size for angiotensin receptor blockers (arbs) has seen consistent growth in recent years. There is an anticipated rise from $8.26 billion in 2023 to $8.62 billion in 2024, given a compound annual growth rate (CAGR) of 4.3%. The past growth can be credited to factors such as the surge in hypertension cases, proven clinical efficacy, cardiovascular disease populace, renal safeguards, clinical guidelines, the primary use of arbs in treatment, and their cost-effectiveness.

    The market for angiotensin receptor blockers (arbs) is anticipated to witness consistent growth over the coming years, expanding to a worth of $10.28 billion by 2028. This represents a compound annual growth rate (CAGR) of 4.5%. This growth trajectory in the forecast period is the result of precision medical methodologies, emphasis on combination treatments, the global proliferation of the market, deployment of biomarker-based therapies, governmental initiatives, and heightened hypertension awareness. Major trends to look out for in the forecast duration include the adoption of telemedicine, significant investments in research and development, the presence of generic competition and patent expirations, the utilization of digital health solutions to adhere to medication regimens, and the competition from biosimilars.

    Claim Your Free Sample of the Global Angiotensin Receptor Blockers ARBs Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

    What Are the Primary Growth Drivers for the angiotensin receptor blockers arbs Market?

    The anticipated rise in cardiovascular disease cases is set to fuel the expansion of the angiotensin receptor blockers market. Cardiovascular disease (CVD) includes any disorder impacting the heart or blood vessels. These conditions are often linked to the formation of fatty deposits within arteries (atherosclerosis) and the heightened possibility of blood clots. Angiotensin receptor blockers reduce blood pressure and enhance the heart’s ability to pump blood by aiding vein and artery relaxation, thus, lowering the risk of cardiovascular disease. For example, the American College of Cardiology, a professional medical organization in the US, stated in August 2022 that the predicted frequency of cardiovascular risk factors and disease is set to significantly increase in the US by 2060. Hence, the escalating prevalence of cardiovascular diseases is propelling the expansion of the angiotensin receptor blockers market.

    What Are the Defining Segments of the Angiotensin Receptor Blockers ARBs Market?

    1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

    2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

    3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

    What Trends Are Revolutionizing Standards in the Angiotensin Receptor Blockers ARBs Market?

    Gaining popularity in the angiotensin receptor blockers market is largely due to product innovation, a key trend. Major players in the market like Novartis AG, a pharmaceutical company based in Switzerland, are concentrating on creating innovative solutions to consolidate their market position. For instance, in February 2021, they launched Entresto (sacubitril/valsartan), which has been approved by the United States Food and Drug Administration for an expanded indication. This approval is to cut down the risk of cardiovascular death and hospitalization cases for chronic heart failure in adult patients. The clinical advantages are more pronounced in patients having a LVEF which is lower than normal. Entresto becomes the first and exclusive therapy approved in the U.S. for treating patients having heart failure as per defined guidelines. This includes patients with reduced ejection fraction (HFrEF) heart failure and several patients with preserved ejection fraction (HFpEF) heart failure.

    Order Now for Fast Delivery of Your Angiotensin Receptor Blockers ARBs Market Report!

    https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

    What Regions Are Propelling Growth in the Angiotensin Receptor Blockers ARBs Industry?

    North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2023. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Angiotensin Receptor Blockers ARBs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the angiotensin receptor blockers arbs market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Angiotensin Receptor Blockers ARBs Market Include

    1. Angiotensin Receptor Blockers ARBs Market Executive Summary

    2. Angiotensin Receptor Blockers ARBs Market Segments

    3. Angiotensin Receptor Blockers ARBs Market Size And Template Market Growth Rate

    4. Key Angiotensin Receptor Blockers ARBs Market Trends

    5. Major Angiotensin Receptor Blockers ARBs Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Angiotensin Receptor Blockers ARBs Market

    26. Top Angiotensin Receptor Blockers ARBs Companies

    27. Angiotensin Receptor Blockers ARBs Market Opportunities And Strategies

    28. Angiotensin Receptor Blockers ARBs Market, Conclusions And Recommendations

    29. Appendix

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Global Angiotensin Receptor Blockers (ARBs) Market Analysis: Estimated Market Size And Growth Rate

    Global Angiotensin Receptor Blockers (ARBs) Market Analysis: Estimated Market Size And Growth Rate

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    The angiotensin receptor blockers (ARBs) market is witnessing steady growth, driven by rising cardiovascular disease incidence, innovative product solutions, and evolving treatment paradigms. Let’s explore the dynamics and trends shaping this dynamic landscape.

    Cardiovascular Disease Incidence: Fueling Market Surge

    • The escalating incidence of cardiovascular diseases underscores the importance of ARBs in disease management.
    • ARBs help lower blood pressure and reduce the risk of cardiovascular events, making them pivotal in combating heart-related ailments.
    • According to the American College of Cardiology, cardiovascular risk factors and disease rates are projected to rise significantly in the United States by 2060, highlighting the urgency for effective treatments.

    Key Players and Market Landscape

    • Major companies like Pfizer Inc., Novartis AG, and AstraZeneca Plc. lead innovations in ARB development and distribution.
    • Product diversification, strategic partnerships, and research investments drive market competitiveness and expansion.
    • Market segmentation includes ARB types, applications, and end-user segments, catering to diverse patient needs and healthcare settings.

    Innovative Product Solutions: Driving Market Growth

    • Product innovation emerges as a key trend, with companies focusing on developing novel ARB formulations and combinations.
    • Novartis AG’s launch of Entresto (sacubitril/valsartan) underscores the importance of innovative therapies in cardiovascular care.
    • Entresto’s expanded indication by the FDA for chronic heart failure treatment marks a significant milestone in ARB therapy advancement.

    Market Growth and Projections

    • The ARBs market exhibits steady growth, with projections indicating sustained expansion.
    • From $8.26 billion in 2023, the market is poised to reach $8.62 billion in 2024, reflecting a CAGR of 4.3%.
    • Anticipated growth to $10.28 billion by 2028, with a CAGR of 4.5%, highlights the market’s resilience and potential.

    View More On The Angiotensin Receptor Blockers (ARBs) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

    Trends Shaping Market Evolution

    • Telemedicine adoption, research and development investments, and digital health solutions drive market evolution and patient care.
    • Focus on combination therapies, precision medicine approaches, and biomarker-based treatment strategies optimize treatment outcomes.
    • Generic competition, patent expirations, and biosimilar introductions challenge market incumbents and foster innovation.

    Regional Dynamics and Market Outlook

    • North America leads the ARBs market, with robust growth prospects in emerging markets.
    • Asia-Pacific’s increasing healthcare expenditure, government initiatives, and awareness of hypertension drive market expansion and adoption.

    Embracing the Future of ARBs

    • As the ARBs market evolves, stakeholders must prioritize patient-centric care, accessibility, and treatment affordability.
    • Collaboration between healthcare providers, policymakers, and industry leaders is essential to address cardiovascular disease burden and improve patient outcomes.
    • By embracing technological advancements, fostering research and development, and advocating for cardiovascular health, the industry can drive positive health outcomes and enhance quality of life globally.

    In conclusion, the angiotensin receptor blockers market represents a dynamic landscape characterized by innovation, growth, and evolving treatment approaches. By leveraging technological advancements, fostering collaborative partnerships, and prioritizing patient needs, the industry can unlock new opportunities and pave the way for improved cardiovascular care and patient well-being worldwide.

    Request A Sample Of The Global Angiotensin Receptor Blockers (ARBs) Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=8943&type=smp